Table 4

Predictors of remission at 5-year follow-up

Age-adjusted univariate
Predictor(All patients n=197, remission: n=35)
Male gender2.32 (1.09 to 4.94)*
DAS28 baseline (per stdz unit)1.10 (0.72 to 1.67)
DAPSA baseline (per stdz unit)0.94 (0.63 to 1.40)
Polyarthritis at baseline0.51 (0.24 to 1.12)
Axial disease at baseline2.46 (0.89 to 6.77)
Mono/oligoarticular disease at baseline1.70 (0.81 to 3.57)
SJC baseline0.96 (0.88 to 1.05)
TJC baseline0.98 (0.92 to 1.04)
HAQ baseline (per stdz unit)0.78 (0.52 to 1.18)
Global VAS baseline (per stdz unit)1.06 (0.73 to 1.53)
Pain VAS baseline (per stdz unit)1.11 (0.96 to 1.01)
Months of delay (per stdz unit)0.97 (0.91 to 1.02)
NSAID after baseline2.13 (0.83 to 5.47)
DMARD ever0.71 (0.33 to 1.49)
MTX ever0.97 (0.47 to 2.03)
Biological agent ever2.18 (0.70 to 6.76)
Age baseline (per 10 years)0.84 (0.63 to 1.12)
  • Values are OR (95% CI).

  • *Statistically significant, p<0.05.

  • Multivariate analysis not performed.

  • DAPSA, Disease Activity Index for Psoriatic Arthritis; DAS28, Disease Activity Score including 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; SJC, swollen joint count; stdz, standardised; TJC, tender joint count; VAS, visual analogue scale.